These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 8304982

  • 1. Phorbol regulation of topoisomerases I and II in human leukemia cells. Studies in an additional cell pair sensitive or resistant to phorbol-induced differentiation.
    Ellis AL, Altschuler E, Bales E, Hinds M, Mayes J, Soares L, Zipf TF, Zwelling LA.
    Biochem Pharmacol; 1994 Jan 20; 47(2):387-96. PubMed ID: 8304982
    [Abstract] [Full Text] [Related]

  • 2. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
    Zwelling LA, Hinds M, Chan D, Altschuler E, Mayes J, Zipf TF.
    Cancer Res; 1990 Nov 15; 50(22):7116-22. PubMed ID: 2171756
    [Abstract] [Full Text] [Related]

  • 3. Effect of bryostatin 1 on drug-induced, topoisomerase II-mediated DNA cleavage and topoisomerase II gene expression in human leukemia cells.
    Zwelling LA, Chan D, Altschuler E, Mayes J, Hinds J, Pettit GR.
    Biochem Pharmacol; 1991 Mar 01; 41(5):829-32. PubMed ID: 1847817
    [Abstract] [Full Text] [Related]

  • 4. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Zwelling LA, Chan D, Hinds M, Mayes J, Silberman LE, Blick M.
    Cancer Res; 1988 Dec 01; 48(23):6625-33. PubMed ID: 2846155
    [Abstract] [Full Text] [Related]

  • 5. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-alpha is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity.
    Chresta CM, Hall BF, Francis GE.
    Leukemia; 1995 Aug 01; 9(8):1373-81. PubMed ID: 7643627
    [Abstract] [Full Text] [Related]

  • 6. Time course of phorbol-12-myristate-13-acetate (PMA)-induced down-regulation of topoisomerase II in human leukemia cells.
    Ellis AL, Zwelling LA.
    Biochem Pharmacol; 1994 Nov 01; 48(9):1842-5. PubMed ID: 7980655
    [Abstract] [Full Text] [Related]

  • 7. Rapid increase in the activity of DNA topoisomerase I, but not topoisomerase II, in HL-60 promyelocytic leukemia cells treated with a phorbol diester.
    Gorsky LD, Cross SM, Morin MJ.
    Cancer Commun; 1989 Nov 01; 1(2):83-92. PubMed ID: 2561736
    [Abstract] [Full Text] [Related]

  • 8. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4067-77. PubMed ID: 2825713
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A, Ibrahim N, Patel M, Li XG, Gupta E, Mendoza J, Pantazis P, Rubin EH.
    Cancer Res; 1997 Nov 15; 57(22):5100-6. PubMed ID: 9371509
    [Abstract] [Full Text] [Related]

  • 10. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
    Aoyama M, Grabowski DR, Isaacs RJ, Krivacic KA, Rybicki LA, Bukowski RM, Ganapathi MK, Hickson ID, Ganapathi R.
    Blood; 1998 Oct 15; 92(8):2863-70. PubMed ID: 9763571
    [Abstract] [Full Text] [Related]

  • 11. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T, Kohno K, Ohga T, Taniguchi K, Kawanami K, Wada M, Kuwano M.
    Cancer Res; 1995 Sep 01; 55(17):3860-4. PubMed ID: 7641205
    [Abstract] [Full Text] [Related]

  • 12. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
    Harker WG, Slade DL, Drake FH, Parr RL.
    Biochemistry; 1991 Oct 15; 30(41):9953-61. PubMed ID: 1655025
    [Abstract] [Full Text] [Related]

  • 13. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
    Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK.
    Oncol Res; 1992 Oct 15; 4(11-12):481-8. PubMed ID: 1338578
    [Abstract] [Full Text] [Related]

  • 14. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC.
    Mol Pharmacol; 1994 Jul 15; 46(1):58-66. PubMed ID: 8058057
    [Abstract] [Full Text] [Related]

  • 15. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N.
    Biochemistry; 1999 Nov 23; 38(47):15573-9. PubMed ID: 10569941
    [Abstract] [Full Text] [Related]

  • 16. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
    Riou JF, Grondard L, Petitgenet O, Abitbol M, Lavelle F.
    Biochem Pharmacol; 1993 Sep 01; 46(5):851-61. PubMed ID: 8396937
    [Abstract] [Full Text] [Related]

  • 17. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E, Mayes J, Sie KL, Meltzer PS, Trent JM.
    J Natl Cancer Inst; 1990 Oct 03; 82(19):1553-61. PubMed ID: 1976136
    [Abstract] [Full Text] [Related]

  • 18. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S, Benchokroun Y, Larsen AK.
    Mol Pharmacol; 1995 May 03; 47(5):898-906. PubMed ID: 7746278
    [Abstract] [Full Text] [Related]

  • 19. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
    Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT.
    Biochemistry; 1988 Nov 29; 27(24):8861-9. PubMed ID: 2853972
    [Abstract] [Full Text] [Related]

  • 20. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J, Riou G.
    Biochem Pharmacol; 1991 Jun 15; 41(12):1967-79. PubMed ID: 1645555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.